Table 1.
Multivariable logistic regression for analyzing the demographic and related clinical characteristics for developing BM in patients diagnosed with initial primary NSCLC
| Variables | Number of NSCLC patients (2010–2015) | OR (95% CI) | P value | |
|---|---|---|---|---|
| With bone metastases (%) | Without bone metastases (%) | |||
| Age | 0.976 (0.951–1.001) | 0.055 | ||
| < 50 | 448 (0.71%) | 2143 (3.37%) | 1.00 | – |
| 50–59 | 1547 (2.44%) | 9401 (14.80%) | 0.938 (0.824–1.067) | 0.331 |
| 60–69 | 2443 (3.85%) | 18,108 (28.51%) | 0.929 (0.821–1.051) | 0.243 |
| 70–79 | 2134 (3.36%) | 18,060 (28.44%) | 0.927 (0.818–1.051) | 0.236 |
| ≥ 80 | 914 (1.44%) | 8307 (13.08%) | 0.881 (0.768–1.011) | 0.070 |
| Race | 1.038 (0.994–1.083) | 0 0.089 | ||
| White | 5782 (9.10%) | 45,252 (71.26%) | 1.00 | – |
| Black | 1004 (1.58%) | 6467 (10.18%) | 1.014 (0.935–1.099) | 0.741 |
| Other | 700 (1.10%) | 4300 (6.77%) | 1.060 (0.964–1.166) | 0.226 |
| Marital status | ||||
| Unmarried | 3315 (5.22%) | 25,929 (40.83%) | 1.00 | – |
| Married | 4171 (6.57%) | 30,090 (47.38%) | 1.061 (1.004–1.121) | 0.036 |
| Sex | ||||
| Male | 4375 (6.89%) | 29,133 (45.88%) | 1.00 | – |
| Female | 3111 (4.90%) | 26,886 (42.34%) | 0.815 (0.771–0.861) | < 0.001 |
| Tumor histology | 0.675 (0.641–0.710) | < 0.001 | ||
| Adenocarcinoma | 5231 (8.24%) | 33,262 (52.38%) | 1.00 | – |
| Squamous cell carcinoma | 1874 (2.95%) | 21,274 (33.50%) | 0.516 (0.485–0.549) | < 0.001 |
| Other | 381 (0.60%) | 1483 (2.34%) | 1.005 (0.873–1.156) | 0.948 |
| Laterality | 0.972 (0.923–1.023) | 0 0.269 | ||
| Left | 3008 (4.74%) | 22,705 (35.75%) | 1.00 | – |
| Right | 4326 (6.81%) | 32,871 (51.76%) | 0.964 (0.913–1.019) | 0.194 |
| Paired | 152 (0.24%) | 443 (0.70%) | 0.860 (0.695–1.063) | 0.164 |
| T stage | 1.287 (1.251–1.324) | < 0.001 | ||
| T1 | 616 (0.97%) | 15,456 (24.34%) | 1.00 | – |
| T2 | 2039 (3.21%) | 19,431 (30.60%) | 1.798 (1.631–1.983) | < 0.001 |
| T3 | 2088 (3.29%) | 11,120 (17.51%) | 2.272 (2.052–2.516) | < 0.001 |
| T4 | 2743 (4.32%) | 10,012 (15.77%) | 2.536 (2.290–2.809) | < 0.001 |
| N stage | 1.568 (1.527–1.610) | < 0.001 | ||
| N0 | 1484 (2.34%) | 30,334 (47.77%) | 1.00 | – |
| N1 | 650 (1.02%) | 5881 (9.26%) | 1.709 (1.544–1.892) | < 0.001 |
| N2 | 3732 (5.88%) | 15,400 (24.25%) | 2.862 (2.671–3.068) | < 0.001 |
| N3 | 1620 (2.55%) | 4404 (6.93%) | 3.457 (3.170–3.771) | < 0.001 |
| Grade | 1.272 (1.218–1.328) | < 0.001 | ||
| 1 | 356 (0.56%) | 6088 (9.59%) | 1.00 | – |
| 2 | 2282 (3.59%) | 22,606 (35.60%) | 1.470 (1.298–1.666) | < 0.001 |
| 3 | 4681 (7.37%) | 26,428 (41.62%) | 1.695 (1.500–1.915) | < 0.001 |
| 4 | 167 (0.26%) | 897 (1.41%) | 1.568 (1.247–1.971) | < 0.001 |
| Brain metastases | ||||
| No | 5735 (9.03%) | 52,082 (82.01%) | 1.00 | – |
| Yes | 1751 (2.76%) | 3937 (6.20%) | 1.946 (1.812–2.089) | < 0.001 |
| Liver metastases | ||||
| No | 5818 (9.16%) | 54,583 (85.95%) | 1.00 | – |
| Yes | 1668 (2.63%) | 1436 (2.26%) | 5.846 (5.383–6.349) | < 0.001 |
| Lung metastases | ||||
| No | 5155 (8.12%) | 51,079 (80.43%) | 1.00 | – |
| Yes | 2331 (3.67%) | 4940 (7.78%) | 2.052 (1.917–2.197) | < 0.001 |